New insights into progressive multifocal leukoencephalopathy

Current Opinion in Neurology

Volumn 17, Issue 3, 2004, Pages 365-370

  Koralnik, Igor J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AIDS; Cytotoxic T lymphocytes; HIV; JC virus; Polyomavirus; Progressive multifocal leukoencephalopathy

Indexed keywords

ABACAVIR; ALPHA2B INTERFERON; CD8 ANTIGEN; CIDOFOVIR; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; INDINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TOPOTECAN; ZIDOVUDINE;

CELLULAR IMMUNITY; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; JC VIRUS; MACROPHAGE; MORTALITY; POLYMERASE CHAIN REACTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; STATISTICAL SIGNIFICANCE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HIV INFECTIONS; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 2642572579     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200406000-00019     Document Type: Review

References (52)

1. Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987; 107:78-87.
2. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 (Suppl. 2):115-121.
3. Gibson PE, Knowles WA, Hand JF, Brown DW. Detection of JC virus DNA in the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Med Virol 1993; 39:278-281.
4. McGuire D, Barhite S, Hollander H, Miles M. JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy [published erratum appears in Ann Neurol 1995 May; 37:687]. Ann Neurol 1995; 37:395-399.
5. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003; 9 (Suppl. 1):88-92. This article reviews the clinical course of PML and defines a consensus terminology based on clinical, radiological, virological and pathological data.
6. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9 (Suppl. 1):47-53. This is a large epidemiological study of PML in Italy, which provides interesting data on survival.
7. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36:1047-1052. This is a large epidemiological study of PML in Spain, which provides interesting data on prognostic factors.
8. Pagnoux C, Hayem G, Roux F, et al. JC virus leukoencephalopathy complicating Wegener's granulomatosis. Joint Bone Spine 2003; 70:376-379.
9. Shitrit D, Nirit L, Shiran SI, et al. Progressive multifocal leukoencephalopathy in a lung transplant recipient. J Heart Lung Transplant 2003; 22:946-950.
10. Steurer M, Clausen J, Gotwald T, et al. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation 2003; 76:435-436.
11. Elloumi M, Ayadi N, Mhiri C, et al. Progressive multifocal leukoencephalitis complicating polymyositis [in French]. Presse Med 2003; 32:162-163.
12. Koralnik IJ, Schellingerhout D, Frosch MP. Case records of the Massachusetts General Hospital. Case 9-2004: A 66-year-old man with progressive neurologic defects. N Engl J Med 2004; (in press).
13. Shankar SK, Satishchandra P, Mahadevan A, et al. Low prevalence of progressive multifocal leukoencephalopathy in India and Africa: is there a biological explanation? J Neurovirol 2003; 9 (Suppl. 1):59-67.
14. Hoffmann C, Horst HA, Albrecht H, Schlote W. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003; 74:1142-1144.
15. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9 (Suppl. 1):73-80. The authors have an interesting insight regarding HAART-induced immune reconstitution and the development of PML.
16. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003; 9 (Suppl. 1):25-31. A case presentation of inflammatory reactions in PML, and a review of the literature of PML arising in the setting of the immune reconstitution inflammatory syndrome.
17. Cinque P, Pierotti C, Vigano MG, et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7:358-363.
18. Koralnik IJ. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J Neurovirol 2002; 8 (Suppl. 2):59-65.
19. Gasnault J, Kahraman M, de Goer de Herve MG, et al. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 2003; 17:1443-1449. A study of the role of CD4 T cells in PML.
20. Gasnault J, Taoufik Y, Goujard C, et al. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 1999; 5:421-429.
21. Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001; 75:3483-3487.
22. Koralnik IJ, Du Pasquier RA, Kuroda MJ, et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 2002; 168:499-504.
23. Du Pasquier RA, Clark KW, Smith PS, et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7:318-322.
24. Du Pasquier RA, Kuroda MJ, Schmitz JE, et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1p36 in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol 2003; 77:11918-11926. A comprehensive CTL epitope mapping study of the JCV major capsid protein, VP1, and the characterization of the immunodominant epitope VP1p36.
25. Royal W III, Dupont B, McGuire D, et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9:411-419. This is a treatment study of PML with topothecan, which was associated with considerable side-effects, and had disappointing results.
26. Osorio S, de la Camara R, Golbano N, et al. Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. Bone Marrow Transplant 2002; 30:963-966.
27. Roberts MT, Carmichael A, Lever AM. Prolonged survival in AIDS-related progressive multifocal leucoencephalopathy following anti-retroviral therapy and cidofovir. Int J Antimicrob Agents 2003; 21:347-349.
28. Herrlinger U, Schwarzler F, Beck R, et al. Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease. J Neurol 2003; 250:612-614.
29. Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997; 41:587-593.
30. Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998; 4:451-456.
31. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16:1791-1797.
32. Gasnault J, Kousignian P, Kahraman M, et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 2001; 7:375-381.
33. Geschwind MD, Skolasky RI, Royal WS, McArthur JC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 2001; 7:353-357.
34. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team [see Comments]. N Engl J Med 1998; 338:1345-1351.
35. Aksamit AJ. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol 2001; 7:386-390.
36. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998; 44:341-349.
37. Clifford DB. Challenges for clinical trials to treat progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9 (Suppl. 1):68-72. This study presents a blueprint for organizing meaningful treatment trials for PML in the future.
38. Gray F, Chretien F, Vallat-Decouvelaere AV, Scaravilli F. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003; 62:429-440. A neuropathological study of HIV-infected patients that highlights the recent evolution of the disease spectrum in patients treated with HAART.
39. Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003; 13:195-210.
40. Du Pasquier RA, Corey S, Margolin DH, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003; 61:775-782. This is the first description of a productive infection of neurons by JCV.
41. Tyler KL. The uninvited guest: JC virus infection of neurons in PML. Neurology 2003; 61:734-735.
42. Richardson EP Jr, Webster HD. Progressive multifocal leukoencephalopathy: its pathological features. Prog Clin Biol Res 1983; 105:191-203.
43. Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leukoencephalopathy. Brain 1958; 81:93-127.
44. Holmberg CA, Gribble DH, Takemoto KK, et al. Isolation of simian virus 40 from rhesus monkeys (Macaca mulatta) with spontaneous progressive multifocal leukoencephalopathy. J Infect Dis 1977; 136:593-596.
45. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186 (Suppl. 2):S180-S186.
46. Dorries K, Sbiera S, Drews K, et al. Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol 2003; 9 (Suppl. 1):81-87. The authors investigated which type of white blood cells may be transporting JCV in the circulation.
47. Koralnik IJ, Schmitz JE, Lifton MA, et al. Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals. J Neurovirol 1999; 5:430-435.
48. Wei G, Liu CK, Atwood WJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B lymphocytes, but not to T lymphocytes. J Neurovirol 2000; 6:127-136.
49. Messam CA, Hou J, Gronostajski RM, Major EO. Lineage pathway of human brain progenitor cells identified by JC virus susceptibility. Ann Neurol 2003; 53:636-646.
50. Komagome R, Sawa H, Suzuki T, et al. Oligosaccharides as receptors for JC virus. J Virol 2002; 76:12992-13000.
51. Baum S, Ashok A, Gee G, et al. Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9 (Suppl. 1):32-37.
52. Khalili K, Del Valle L, Otte J, et al. Human neuratropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene 2003; 22:5181-5191.